Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success

Geron Corporation (NASDAQ:GERN) is one of the most promising penny stocks under $5 to buy. On February 25, Geron Corporation reported earnings results for Q4 and the full year of 2025, fueled by the commercial success of its first-in-class telomerase inhibitor, RYTELO. The company achieved $48 million in net product revenue for Q4 and $183.6 million for the full year. This growth was supported by a 9% increase in demand and the expansion of its ordering accounts to ~1,300.

Strategically, Geron underwent a significant transition in late 2025 to optimize its path toward sustainability. The company implemented a workforce reduction of ~one-third to lower future operating expenses while maintaining its commercial focus. R&D expenses decreased as costs for RYTELO shifted from clinical development to capitalized commercial manufacturing. Meanwhile, the company continues to build a robust body of scientific evidence, with 10+ investigator-sponsored trials underway and new data expected in H2 2026 regarding RYTELO’s use in real-world settings and earlier lines of treatment.

For 2026, Geron Corporation (NASDAQ:GERN) reiterated its financial guidance, projecting RYTELO net product revenue between $220 and $240 million. Beyond US commercial growth, the company is focused on the IMpactMF interim analysis in relapsed/refractory myelofibrosis and exploring pathways to bring RYTELO to international markets.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company that develops therapeutic products for oncology. It offers RYTELO, which is a telomerase inhibitor for low to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.